Agenus Inc. (NASDAQ:AGEN - Get Free Report) has been assigned a consensus rating of "Hold" from the six ratings firms that are currently covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $10.00.
A number of analysts have commented on AGEN shares. B. Riley reduced their price objective on Agenus from $42.00 to $18.00 and set a "buy" rating for the company in a research report on Wednesday, August 14th. StockNews.com downgraded Agenus from a "hold" rating to a "sell" rating in a research report on Monday, August 12th. Finally, HC Wainwright cut their target price on Agenus from $8.00 to $7.00 and set a "neutral" rating for the company in a research report on Tuesday, November 12th.
Check Out Our Latest Stock Report on Agenus
Hedge Funds Weigh In On Agenus
Several institutional investors have recently bought and sold shares of the business. Point72 DIFC Ltd acquired a new stake in shares of Agenus in the 2nd quarter valued at $51,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Agenus in the 2nd quarter valued at $106,000. EP Wealth Advisors LLC acquired a new stake in shares of Agenus during the third quarter worth $55,000. HighTower Advisors LLC grew its stake in shares of Agenus by 46.1% during the third quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company's stock worth $122,000 after purchasing an additional 7,530 shares during the period. Finally, Blair William & Co. IL acquired a new stake in shares of Agenus during the second quarter worth $441,000. Institutional investors own 61.46% of the company's stock.
Agenus Stock Up 3.9 %
AGEN opened at $2.67 on Thursday. The stock's 50 day moving average price is $4.53 and its two-hundred day moving average price is $8.46. Agenus has a 12-month low of $2.50 and a 12-month high of $19.69. The firm has a market capitalization of $62.64 million, a P/E ratio of -0.24 and a beta of 1.39.
Agenus Company Profile
(
Get Free ReportAgenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Further Reading
Before you consider Agenus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.
While Agenus currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
